FDA/NIH Guidance
- November 10, 2022
-
FDA/NIH Guidance
The COVID-19 Treatment Guidelines Panel’s Statement on Omicron Subvariants, Pre-Exposure Prophylaxis, and Therapeutic Management of Nonhospitalized Patients With COVID-19 - Read More
- October 25, 2022
-
FDA/NIH Guidance
EVUSHELD COVID-19 Treatment Available for Moderately to Severely Immunocompromised Individuals The monoclonal antibody treatment is authorized as pre-exposure prophylaxis to prevent COVID-19.
- Read More
- September 26, 2022
-
FDA/NIH Guidance
NIH Guidance on Therapeutic Management of Nonhospitalized Adults With COVID-19 - Read More
- May 4, 2022
-
FDA/NIH Guidance
FDA Updates on Paxlovid for Health Care Providers - Read More
- May 4, 2022
-
FDA/NIH Guidance
Paxlovid Patient Eligibility Screening Checklist Tool for Prescribers - Read More
- December 28, 2021
-
FDA/NIH Guidance
FDA Approves New Pill Form Antivirals for COVID-19 HHS pauses monoclonal antibody medications unlikely to work against Omicron variant.
- Read More